The board of directors of Eli Lilly (LLY) and Company approved a new $15B share repurchase program. The company’s prior $5B share repurchase ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
Azelaprag, the company’s main clinical candidate, is an oral apelin receptor agonist designed to amplify the weight loss ...
Amazon's stock has surged nearly 50% YTD, with 25% of this increase in the last two months alone, driven by a Q3 earnings ...
In the U.S., the chorus of opposition against the proposed merger continues to grow and now includes the CEOs of Roche and ...
Eli Lilly will launch Mounjaro in India in 2025. The drug treats type 2 diabetes and obesity. Lilly received marketing ...
Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not ...
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
Lilly's rival Danish firm Novo Nordisk is also working to bring its obesity drug Wegovy (Semaglutide) to India soon, and ...